首页> 外文会议>International Mass Spectrometry Conference >PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS

【24h】

PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

Mass spectrometry-based proteomics is an indispensable tool for molecular, cellular biology and for the emerging field of clinical medicine. Especially, phosphoproteome is one of key signatures to understand the mode of action and mechanism of drug resistance of kinase inhibitors at the molecular level, pathway level and system level.

机译：基于质谱的蛋白质组学是一种不可或缺的分子，细胞生物学和临床医学领域的不可或缺的工具。特别是，磷蛋白质是了解在分子水平，途径水平和系统水平下激酶抑制剂的动作和机制的关键签名之一。

著录项

来源
《International Mass Spectrometry Conference》|2018年|p1-627|共2页
会议地点
作者
Jun Adachi; Yuichi Abe; Maiko Nagano; Junko Isoyama; Marina Kishida; Takeshi Tomonaga;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类分析化学;
关键词
peptide fractionation; StageTip; phosphoproteome; non-small cell lung cancer; kinase-substrate enrichment analysis;

机译：肽分馏;酸纤维蛋白;磷酸酯组;非小细胞肺癌;激酶 - 底物富集分析;

相似文献

外文文献
中文文献
专利

1. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials [J] . Yu Shuhan, Xu Qini, Yuan Yun, Current medical research and opinion . 2016,第12期

机译：在先前治疗的晚期非小细胞肺癌中，基于厄洛替尼的靶向双重药物与单独使用厄洛替尼的比较：13项随机对照试验的荟萃分析
2. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarker-stratified, randomised phase 3 trial [J] . GregorcV., NovelloS., LazzariC., The lancet oncology . 2014,第7期

机译：蛋白质组学特征在二线厄洛替尼或化疗（PROSE）治疗的非小细胞肺癌患者中的预测价值：一项生物标记物分层的随机3期试验
3. Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer [J] . Yi-Ting Wang, Szu-Hua Pan, Chia-Feng Tsai, Scientific reports. . 2017,第1期

机译：磷蛋白质可以揭示HMGA1，CK2底物，作为非小细胞肺癌的耐药靶标
4. PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS [C] . Jun Adachi, Yuichi Abe, Maiko Nagano, International Mass Spectrometry Conference . 2018

机译：用厄洛替尼处理的非小细胞肺癌细胞的磷脂蛋白酶揭示了耐药象征和潜在目标
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials [O] . Jian-Wei Gao, Ping Zhan, Xiang-Yu Qiu, 2017

机译：在先前治疗的晚期非小细胞肺癌中基于厄洛替尼的双重靶向治疗与单独使用厄洛替尼的比较：一项来自24个随机对照试验的荟萃分析
7. Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials [O] . Jian-Wei Gao, Ping Zhan, Xiang-Yu Qiu, 2017

机译：基于Erlotinib的双峰靶向治疗与Erlotinib在此先前治疗的晚期非小细胞肺癌中：来自24项随机对照试验的Meta分析

PHOSPHOPROTEOMICS OF NON-SMALL-CELL LUNG CANCER CELLS TREATED WITH ERLOTINIB REVEALS DRUG-RESISTANT SIGNATURES AND POTENTIAL TARGETS

摘要

著录项

相似文献

相关主题

期刊订阅